China’s Triastek and Germany’s BioNTech Join Forces for 3D Printed Oral Therapeutics
Triastek Inc., a China-based pharmaceutical company specializing in 3D printing technology, has entered into a...
RemeGen’s Telitacicept Earns Full NMPA Approval for RA Treatment and PMN Clinical Study Green Light
RemeGen (HKG: 9995), a biopharmaceutical company based in China, has announced that the National Medical...
NMPA Suspends Import and Sale of SAMO S.p.A Knee and Hip Prosthesis Systems
The National Medical Products Administration (NMPA) has issued a notice to suspend the import, sale,...
Fosun Pharma and Kite Pharma Inject USD 28.5 Million into Joint Venture for CAR-T Therapy Development
Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196) and Kite Pharma, a subsidiary...
Shanghai Medicilon and Jiangsu Hengrui Join Forces to Advance Pre-Clinical Drug Evaluation
Shanghai Medicilon Biomedical Co., Ltd, a leading biopharmaceutical company based in China, has entered into...
AccurEdit Therapeutics Receives CDE Approval for Gene Editing Drug ART001 Targeting Amyloidosis
AccurEdit Therapeutics (Suzhou) Co., Ltd, a leading specialist in gene editing therapies based in China,...
Luye Pharma Group Secures RMB 1.6 Billion Investment to Boost Financials and R&D
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that...
ICER Analysis Flags Pfizer’s ATTR-CM Therapy Vyndamax/Vyndaqel as Costly, Suggests Price Cut
The Institute for Clinical and Economic Review (ICER), a US-based non-profit organization specializing in drug...
Beijing Launches Bio-Park: A New Hub for International Pharmaceutical Innovation
Beijing has unveiled an ambitious plan to construct Bio-Park, a state-of-the-art international pharmaceutical innovation park...
MicroPort CardioFlow Secures Exclusive Distribution Rights for Evermend Occluders in China
MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced...
China’s NMPA and NHC Implement New Rules for Temporary Import of Urgent Medical Devices
The National Medical Products Administration (NMPA) and the National Health Commission have issued the Management...
Jiangsu QYuns Therapeutics and Huadong Medicine Partner on QX005N Injection Development and Promotion
Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has entered...
Innovent Biologics’ Mazdutide Achieves Primary and Secondary Endpoints in Phase III T2D Trial
Innovent Biologics Inc. (Innovent) (HKG: 1801), a leading biopharmaceutical company based in China, has announced...
China Unveils Ambitious Healthcare Reforms at 20th Central Committee Plenary Session
The third plenary session of the 20th Central Committee of the Communist Party of China...
Jiangsu Hengrui Receives NMPA Approval to Study CDK 4/6 Inhibitor Dalpiciclib in Combination with HRS-1358 for Breast Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has received...
Hansoh Pharmaceutical’s EGFR Inhibitor Ameile Files for Adjuvant Therapy Approval with NMPA
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading biopharmaceutical company based in China, has...
NMPA Approves Chengdu Chipscreen’s Bilessglu for Type 2 Diabetes in Combination with Metformin
The National Medical Products Administration (NMPA) has granted approval for Shenzhen Chipscreen Biosciences Co., Ltd...
Eisai Forges Partnerships with Chinese Firms to Strengthen Alzheimer’s Disease Market Presence
Eisai Co., Ltd, (TYO: 4523) a Japanese pharmaceutical company, has announced separate strategic partnerships with...
MedSci Healthcare’s Bioon.com Partners with Wego Group to Boost Local Innovation and Product Promotion
MedSci Healthcare Co., Ltd (HKG: 2415), a Chinese healthcare company, has announced that its subsidiary,...
Rona Therapeutics Secures USD 35 Million in Series A+ Round to Advance Nucleic Acid Therapies
Rona Therapeutics, a Shanghai-based nucleic acid drug developer, has secured USD 35 million in a...